RESUMO
We have examined the matrix proteins of A/Okuda/57, A/Finland/4/74 and A/New Jersey/8/76 viruses and several recombinant strains by radioiodination of the purified polypeptides followed by tryptic peptide mapping. The method is rapid and requires only small amounts of material. Reproducible differences were detected between the matrix proteins of the above parents and allowed origin of the matrix proteins of the recombinant viruses to be determined. The possible use of matrix protein identity as a marker in recombination work is discussed.
Assuntos
Vírus da Influenza A/genética , Nucleoproteínas/genética , Recombinação Genética , Proteínas Virais/genética , Mapeamento Cromossômico , Genes Virais , Radioisótopos do Iodo , Peptídeos/genéticaRESUMO
The internal matrix proteins of A/Okuda/57, A/Finland/4/74 and A/New Jersey/8/76 viruses and several recombinant strains have been examined by radioiodination of the purified proteins followed by peptide mapping. The method is rapid and requires only small amounts of material. Reproducible differences were detected between the matrix proteins of the above parents and allowed the origin of the matrix proteins of the recombinant viruses to be determined. The use of matrix protein identity as a marker in recombination work and its possible correlation with biological properties of the virus is discussed.
Assuntos
Vírus da Influenza A/genética , Recombinação Genética , Proteínas Virais/análise , Cruzamentos Genéticos , Eletroforese em Papel , Vírus da Influenza A/análise , Vírus da Influenza A/isolamento & purificação , Fragmentos de Peptídeos/análise , TripsinaRESUMO
Groups of 45 adult volunteers were vaccinated intranasally with a single dose of either "Alice" or WRL 105 strain live influenza vaccines. Seroconversion rates against A/Scotland/840/74 were significantly greater following administration of WRL 105 but seroconversion rates against A/England/42/72, A/Port Chalmers/1/73, A/Finland/4/74, A/Victoria/3/75, and A/England/864/75 did not differ significantly between the two vaccines. Poor antibody responses were elicited by both "Alice" and WRL 105 strains against A/Victoria/3/75 and A/England/864/75. No severe reactions followed the administration of either vaccine.
Assuntos
Anticorpos Antivirais/isolamento & purificação , Vacinas contra Influenza/administração & dosagem , Orthomyxoviridae/imunologia , Administração Intranasal , Adolescente , Adulto , Anticorpos Heterófilos/isolamento & purificação , Reações Antígeno-Anticorpo , Ensaios Clínicos como Assunto , Feminino , Humanos , Imunidade Ativa , Esquemas de Imunização , Imunização Secundária , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , VacinaçãoAssuntos
Anticorpos Antivirais/biossíntese , Vacinas contra Influenza , Influenza Humana/transmissão , Orthomyxoviridae/isolamento & purificação , Vacinas Atenuadas , Adolescente , Ensaios Clínicos como Assunto , Testes de Inibição da Hemaglutinação , Humanos , Influenza Humana/imunologia , Masculino , PlacebosRESUMO
In the spring of 1975 an outbreak of influenza associated with influenza virus A/Scotland/840/74 virus occurred in a residential college where the previous autumn some students had been immunised with a single intranasal dose of Recombinant WRL 105 (H3N2) (A/Okuda/57xA/Finland/4/74) strain live attenuated infleunza virus vaccine. During the outbreak none of seven students who had been vaccinated suffered from influenza but an influenzal illness did occur in four of eleven who had received placebo nose drops only. Fourfold or greater increases in hemagglutinating inhibiting antibodies between sera collected three weeks after vaccination and those collected three months later following the influenza epidemic were found in one of seven vaccinated and in nine of eleven placebo treated subjects and also in one student who had received neither vaccine nor placebo; a difference in serological response which is statistically significant (p less than 0.01). Thus recombinant WRL 105 live attenuated vaccine was found to have conferred substantial protection against a current wild strain of influenza A virus without causing any appreciable untoward reactions.
Assuntos
Vírus da Influenza A/imunologia , Vacinas contra Influenza/administração & dosagem , Orthomyxoviridae/imunologia , Administração Intranasal , Adolescente , Adulto , Anticorpos Antivirais/análise , Ensaios Clínicos como Assunto , Surtos de Doenças/epidemiologia , Inglaterra , Humanos , Vacinas contra Influenza/uso terapêutico , Influenza Humana/epidemiologia , Influenza Humana/imunologia , Influenza Humana/prevenção & controle , Masculino , Vacinas AtenuadasRESUMO
Strain WRL 105 was prepared by recombination between the A/Finland/4/74 (H3N2) and attenuated A/Okuda/57 (H2N2) strains by a method previously described. A single intranasal dose of WRL 105 strain live attenuated influenza vaccine was administered to volunteers at three dose levels and homologous serum antibody titres and virus excretion were monitored. Doses greater than 10(6.3)EID50 gave 4-fold or greater increases in antibody titre in 80% of seronegative volunteers.
Assuntos
Vírus da Influenza A/imunologia , Vacinas contra Influenza , Orthomyxoviridae/imunologia , Administração Intranasal , Anticorpos Antivirais/análise , Sangue/microbiologia , Testes de Inibição da Hemaglutinação , Humanos , Vírus da Influenza A/isolamento & purificação , Vacinas contra Influenza/administração & dosagem , Nariz/microbiologia , Recombinação GenéticaRESUMO
The immunogenicity, reactivity, and transmissibility of recombinant WRL 105 (H3N2) (A/Okuda/57XA/Finland/4/74) strain live attenuated influenza virus vaccine were studied in adult male volunteers in a residential community in rural England. Thirteen volunteers received a single dose of 10(7.0) E.I.D.50 recombinant WRL 105 vaccine administered as nose drops, and twelve volunteers received placebo. Nine (82%) of eleven volunteers with initial antibody titres of less than or equal to 1/96 showed a significant antibody response to vaccination, but there was no evidence of transmission of vaccine virus to those who received placebo. The incidence and nature of reactions were similar in those who received vaccine and placebo. The vaccine was shown to confer protection against natural infection with a strain exhibition antigenic characteristics equivalent to those of A/Scotland/840/74.
